MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fmed.2026.1735014

Медицинская библиотека · Frontiers in medicine · 2026

Evaluating the diagnostic and prognostic utility of serum DLL1 in acute-on-chronic liver failure patients with bacterial infections.

Huang Juanjun, Wang Zhi, Zhu Wei, Chen Jian

СтатьяПеревод в очереди

Аннотация

BACKGROUND

The diagnosis of bacterial infections (BIs) in patients with acute-on-chronic liver failure (ACLF) remains a formidable clinical challenge, directly impacting mortality rates. Current biomarkers are often confounded by the profound systemic inflammation inherent to ACLF itself. The objective of this study was to evaluate the diagnostic and prognostic utility of serum Delta-like ligand 1 (DLL1) in ACLF patients with BIs.

METHODS

This retrospective diagnostic study utilized a pre-established, prospectively maintained ACLF cohort (n = 168). Serum DLL1 levels were measured with enzyme-linked immunosorbent assays, and diagnostic performance was assessed via receiver operating characteristic (ROC) curve analysis and multivariable regression.

RESULTS

In the ACLF cohort, serum DLL1 concentrations were significantly elevated in BI patients compared with their noninfected counterparts (p < 0.001). Multivariable regression revealed that DLL1 was an independent diagnostic predictor (adjusted OR = 1.982, 95% CI: 1.338-2.937). Moreover, the serum DLL1 level demonstrated substantial discriminative capacity (AUC = 0.815; 95% CI: 0.750-0.879), which improved when this variable was synergistically incorporated into a CRP-DLL1 dual-marker model (AUC = 0.852; p = 0.039 versus DLL1 alone). The stability of the combined model was further evaluated in subgroups with available procalcitonin (PCT) data. Decision curve analysis confirmed the clinical net benefit between probability thresholds from 10 to 70%. Crucially, the levels of DLL1 exhibited only marginal correlations with hepatic function parameters, indicating minimal confounding from liver inflammation, but failed to independently predict mortality in patients with ACLF and BI.

CONCLUSION

Serum DLL1 represents a robust and clinically deployable diagnostic biomarker for BI in patients with ACLF, and its performance is minimally affected by underlying hepatic dysfunction. The synergistic CRP-DLL1 dual-marker model demonstrated enhanced diagnostic discrimination, significantly outperforming the individual biomarkers. Notably, the DLL1 level was not an independent predictor of mortality in this population with concurrent infection.

Для цитирования: Huang Juanjun, Wang Zhi, Zhu Wei, Chen Jian. Evaluating the diagnostic and prognostic utility of serum DLL1 in acute-on-chronic liver failure patients with bacterial infections.. Frontiers in medicine. 2026. DOI: 10.3389/fmed.2026.1735014.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.